Verition Fund Management’s Cymabay Therapeutics CBAY Stock Holding History

Verition Fund Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,170	Closed	-$240K	–	3037
2023 Q4	$240K	Sell	10,170 -527	-5%	-$9.39K	﹤0.01%	1920
2023 Q3	$159K	Buy	+10,697	New	+$142K	﹤0.01%	2036
2023 Q2	–	Sell	-100,342	Closed	-$875K	–	2658
2023 Q1	$875K	Buy	+100,342	New	+$803K	0.01%	995
2022 Q4	–	Sell	-15,800	Closed	-$55K	–	2939
2022 Q3	$55K	Hold	15,800	–	–	﹤0.01%	2687
2022 Q2	$47K	Buy	+15,800	New	+$37.7K	﹤0.01%	2157
2020 Q3	–	Sell	-601,828	Closed	-$2.1M	–	1431
2020 Q2	$2.1M	Buy	+601,828	New	+$1.74M	0.07%	219
2019 Q4	–	Sell	-280,614	Closed	-$1.44M	–	1421
2019 Q3	$1.44M	Buy	+280,614	New	+$1.7M	0.04%	324
2018 Q2	–	Sell	-20,860	Closed	-$271K	–	1390
2018 Q1	$271K	Buy	+20,860	New	+$259K	0.02%	874

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's CBAY Position: Q1 2024 in Review

Verition Fund Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 10,170 shares — an estimated $240K sold.

Verition Fund Management first reported a position in CBAY in Q1 2018 and held it in 8 quarters. The position peaked at $2.1M in Q2 2020. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Verition Fund Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Verition Fund Management sold 10,170 Cymabay Therapeutics shares in Q1 2024, an estimated $240K.
Verition Fund Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 8 quarters.
Verition Fund Management's Cymabay Therapeutics position peaked at $2.1M in Q2 2020.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Verition Fund Management's 13F filing for Q1 2024, filed 14 May 2024.